SXTC Stock Forecast: China Sxt Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 7 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores China Sxt Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (29): Sales and profits are climbing, and climbing faster than before.
Value (6): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SXTC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SXTC, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
SXTC appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SXTC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.2×
- Price / book
- 0.0×
- EV / EBITDA
- —
Cheaper than 88% of US stocks
Cheaper than 99% of US stocks
- Revenue growth (YoY)
- −43.9%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- 21.9%
Higher than 6% of US stocks
Higher than 82% of US stocks
- Return on equity
- −27.5%
- Return on assets
- −15.8%
- Dividend yield
- —
Higher than 29% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
China Sxt Pharmaceuticals, Inc. has a market value of $268K.
China Sxt Pharmaceuticals, Inc. employs 56 people.
Data provided by Twelve Data
SXTC and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SXTC’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own China Sxt Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SXTC
How does Ticker Nerd's model rank SXTC?
As at 21 Nov 2026, China Sxt Pharmaceuticals, Inc. ranks 7 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (29 of 100).
What is the SXTC stock forecast for 2030?
No analyst covering China Sxt Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SXTC are extrapolating price history, which says nothing about the business.
What does China Sxt Pharmaceuticals, Inc. do?
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces. Its product lineup includes directly-oral, after-soaking-oral, fine, and regular TCMP formats, which are distributed under brands such as Suxuantang, Hui Chun Tang, and Tong Ren Tang.
About China Sxt Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces. Its product lineup includes directly-oral, after-soaking-oral, fine, and regular TCMP formats, which are distributed under brands such as Suxuantang, Hui Chun Tang, and Tong Ren Tang. The company serves a range of customers in China, including hospitals, chain pharmacies, pharmaceutical distributors, and commercial pharmaceutical companies, positioning it within the domestic traditional medicine supply chain. Based in Taizhou, Jiangsu, China, China SXT Pharmaceuticals, Inc. operates in a specialized segment of the healthcare market centered on traditional Chinese medicine products.
CEO Mr. Feng Zhou · 56 employees · China · https://www.sxtchina.com